BTK and cardiovascular disorder: Our data strengthen the case for using BTK inhibitors to reduce monocyte infiltration and macrophage activation in acute inflammatory diseases like sepsis, rheumatoid arthritis or cardiovascular disease including myocardial infarction or stroke.